FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $559,000 | -62.6% | 24,946 | -2.2% | 0.10% | -38.5% |
| Q4 2021 | $1,493,000 | +47.4% | 25,513 | +49.2% | 0.16% | +47.7% |
| Q3 2021 | $1,013,000 | -48.5% | 17,099 | -24.5% | 0.11% | -48.6% |
| Q2 2021 | $1,966,000 | +7.7% | 22,647 | +2.3% | 0.21% | +2.4% |
| Q1 2021 | $1,826,000 | -18.1% | 22,144 | -9.7% | 0.21% | -19.8% |
| Q4 2020 | $2,230,000 | +105.7% | 24,519 | -9.6% | 0.26% | +73.2% |
| Q3 2020 | $1,084,000 | +42.1% | 27,121 | +21.9% | 0.15% | +30.7% |
| Q2 2020 | $763,000 | +88.4% | 22,242 | +22.0% | 0.11% | +50.0% |
| Q1 2020 | $405,000 | – | 18,230 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |